Navigation Links
The Corporate Reputation of Pharma in 2012: The Patient Perspective on 29 of the World's Leading Pharma Companies
Date:11/28/2013

DUBLIN, November 28, 2013 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/zm2pwl/the_corporate) has announced the addition of the "The Corporate Reputation of Pharma in 2012: The Patient Perspective" report to their offering.

     (Logo: http://photos.prnewswire.com/prnh/20130307/600769)

A global survey of the views of 600 international, national, and regional patient groups on the corporate reputation of the pharma industry and 29 leading pharma companies

Increasing numbers of pharmaceutical companies are seeking to redefine their relationships with patients, recasting their companies as more patient-centric. PatientView is therefore pleased to ANNOUNCE THE RELEASE of the latest version of its annual review.

- A global survey, conducted mid-November to mid-December 2012, exploring the views of 600 international, national, and regional patient groups from 56 countries (72% from Europe) and differing specialties

- Patient group feedback on the corporate reputation of the pharma industry during 2012.

- Patient group feedback provides rankings of 29 leading pharma companies for six key indicators that influence corporate reputation: patient-centredness; patient information; patient safety; useful products; transparency; and integrity.

- Results for 2012 are compared with those of 2011.

This independent study, funded by PatientView, represents 600 patient groups' latest impressions on the corporate reputation of 29 individual pharma companies and of the pharma industry as a whole. Results for 2012 are compared with 2011. For the purposes of this report, the phrase 'corporate reputation' is defined as the extent to which pharma companies are meeting the expectations of patients and patient groups.

Key findings industry-wide; reputation of pharma fell in 2012

The overall reputation of pharma declined in 2012. Only 34% of the 600 patient groups responding to the 2012 survey state that multinational pharma companies had an Excellent or Good reputation during 2012. The equivalent figure from the 500 patient groups responding to the 2011 survey was 42%. 40% of the 600 respondent patient groups state that the reputation of the pharma industry had declined during 2012. As many as 50% of the 600 respondent patient groups say that industry had a Poor record in 2012 for having fair pricing policies.48% of the 600 respondent patient groups say that industry had a Poor record in 2012 for being transparent.When the 2012 results are compared with those of 2011, the sharpest falls in pharma performance are for the following:

- Managing adverse news about producta 29% fall between 2011 and 2012.

- Having ethical marketing practicesa 23% fall between 2011 and 2012.

- Having a good relationship with the mediaa 19% fall, 2011-2012.

- Several reasons explain why pharma's reputation fell during 2012

Respondent patient groups report:

- a continuing failure to help patients in cash-strapped southern-European countries (such as Greece, Portugal, Romania, and Spain) gain access to medicines;

- a preoccupation by pharma with drugs that offer only short-term health benefits;

- not enough effort being made to discover chemical entities suitable for neglected catchments of patients;

- inappropriate marketing of drugs (including those for off-label indications);

- perceived lack of transparencyespecially in reporting the disappointing results of clinical trials;

- drugs prices that, in some cases, are still unaffordable to many patients or their payersculminating in a general impression that profit comes before making people well.

Companies Mentioned

- Abbott
- Allergan
- Amgen
- AstraZeneca
- Baxter International
- Bayer
- Biogen Idec
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Celgene
- Eli Lilly (Lilly)
- Gilead Sciences
- GlaxoSmithKline (GSK)
- Janssen
- Lundbeck
- Menarini
- Merck & Co (the US company)
- Merck Group (the German company)
- Novartis
- Novo Nordisk
- Pfizer
- Roche
- Sanofi
- Servier
- Shire
- Stada Arzneimittel
- Takeda
- Teva
- UCB


For more information visit http://www.researchandmarkets.com/research/zm2pwl/the_corporate

About Research and Markets
Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: +1-646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals



'/>"/>
SOURCE Research and Markets
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. The Law Firm of Levi & Korsinsky, LLP Announces Investigation into Possible Breaches of Fiduciary Duty by the Board of Gen-Probe Incorporated in Connection with the Sale of the Company to Hologic, Inc.
2. Insmed Incorporated Announces Lifting of Clinical Hold by U.S. Food and Drug Administration on ARIKACE® in Cystic Fibrosis Patients With Pseudomonas Lung Infections
3. Survey Shows eContent Critical to Corporate Strategies
4. Medical Marijuana Inc. (MJNA) Corporate Update on Industry Company Services and Future Development. First Audio-Webcast Interview With SmallCapVoice.com in Quarterly Series
5. Insmed Incorporated Begins Screening Patients For TARGET-NTM U.S. Clinical Trial Of ARIKACE® In Patients With Non-tuberculous Mycobacterial Lung Disease
6. Anatabloc® Retail Expansion with GNC Complete: Product Now Available at all GNC Corporate Stores and GNC.com
7. Faruqi & Faruqi, LLP Announces Investigation of ViroPharma Incorporated
8. Accuray Incorporated to Speak at Jefferies Global Healthcare Conference
9. InfuSystem Holdings Modifies Bylaws to Align with Corporate Governance Best Practices
10. Avaxia Biologics Announces Appointment of Michael D. Rivard as VP Corporate Development
11. Accuray Incorporated to Speak at Wells Fargo Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... India , June 24, 2016 ... Needles Market by Type (Standard Pen Needles, Safety Pen ... Therapy (Insulin, GLP-1, Growth Hormone), Mode of Purchase (Retail, ... by MarketsandMarkets, This report studies the market for the ... expected to reach USD 2.81 Billion by 2021 from ...
(Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, a ... invasive and more durable cerebrospinal fluid treatments, today ... The Series-A funding is led by Innova Memphis, ... and other private investors.  Arkis, new financing will ... and the market release of its in-licensed Endexo® ...
(Date:6/23/2016)... 2016 Any dentist who has made an implant ... process. Many of them do not even offer this as ... high laboratory costs involved. And those who ARE able to ... a high cost that the majority of today,s patients would ... Parsa Zadeh , founder of Dental Evolutions Inc. and inventor ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the ... AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in ... topics including advance care planning, healthcare costs and patient and family engagement. , ...
(Date:6/25/2016)... ... ... Bruton Memorial Library on June 21 due to a possible lice infestation, as reported by ... lice: the parasite’s ability to live away from a human host, and to infest common ... the event that lice have simply gotten out of control. , As lice are a ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... First ... United States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell ... facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin ... injury. Recently, he has implemented orthobiologic procedures as a method for treating his ... of the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits ... terms of the latter, setting the bar too high can result in disappointment, perhaps ... slow progress toward their goal. , Research from PsychTests.com reveals that ...
Breaking Medicine News(10 mins):